Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer

Por Hyman, David M., Spriggs, David R.
Publicado em 2012

Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents

Por Rao, Thapi D., Rosales, Nestor, Spriggs, David R.
Publicado em 2011

A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies

Por Iasonos, Alexia, Wilton, Andrew S, Riedel, Elyn R, Seshan, Venkatraman E, Spriggs, David R
Publicado em 2008

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

Por Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J
Publicado no J Transl Med (2015)

The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials

Por Iasonos, Alexia, Gounder, Mrinal, Spriggs, David R, Gerecitano, John F, Hyman, David M, Zohar, Sarah, O’Quigley, John
Publicado em 2012

Identifying Clinical Improvement in Consolidation Single-arm Phase II Trials in Ovarian Cancer Patients in Second or Greater Clinical Remission

Por Iasonos, Alexia, Sabbatini, Paul, Spriggs, David R., Aghajanian, Carol A., O’Cearbhaill, Roisin E., Hensley, Martee L., Thaler, Howard T.
Publicado em 2012

Novel Monoclonal Antibodies against the Proximal (Carboxy-Terminal) Portions of MUC16

Por Rao, Thapi Dharma, Park, Kay J., Smith-Jones, Peter, Iasonos, Alexia, Linkov, Irina, Soslow, Robert A., Spriggs, David R.
Publicado no Appl Immunohistochem Mol Morphol (2010)

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen

Por Chekmasova, Alena A., Rao, Thapi D., Nikhamin, Yan, Park, Kay J., Levine, Douglas A., Spriggs, David R., Brentjens, Renier J.
Publicado em 2010

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Por Seymour, Lesley, Groshen, Susan, Rosner, Gary L., Sullivan, Daniel M., Spriggs, David R., Reeves, Steven, Gravell, Amy, Ivy, S. Percy, Ratain, Mark J.
Publicado no Clin Cancer Res (2015)

Impact of Prophylactic Conversion to an Extended Infusion Schedule to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients during Carboplatin Retreatment

Por O’Cearbhaill, Roisin, Zhou, Qin, Iasonos, Alexia, Hensley, Martee L., Tew, William P., Aghajanian, Carol, Spriggs, David R., Lichtman, Stuart M., Sabbatini, Paul J.
Publicado no Gynecol Oncol (2009)

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

Por Hyman, David M., Eaton, Anne A., Gounder, Mrinal M., Pamer, Erika G., Pettiford, Jasmine, Carvajal, Richard D., Ivy, S. Percy, Iasonos, Alexia, Spriggs, David R.
Publicado no Oncotarget (2015)

Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials

Por Hyman, David M., Eaton, Anne A., Gounder, Mrinal M., Smith, Gary L., Pamer, Erika G., Hensley, Martee L., Spriggs, David R., Ivy, Percy, Iasonos, Alexia
Publicado em 2014

Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities

Por Eaton, Anne, Iasonos, Alexia, Gounder, Mrinal M, Pamer, Erika G, Drilon, Alexander, Vulih, Diana, Smith, Gary L, Percy Ivy, S., Spriggs, David R, Hyman, David M
Publicado no Clin Cancer Res (2015)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

Por Wang-Gillam, Andrea, Tew, William P., Rothenberg, Mace L., Dupont, Jakob, Cooper, Wendy, Sternas, Lars, Buzenet, Giliane, Sosman, Jeffrey A., Spriggs, David R., Lockhart, Albert Craig
Publicado em 2011

Phase 1 Study of VEGF Trap (Aflibercept) Administered Subcutaneously to Patients with Advanced Solid Tumors

Por Tew, William P., Gordon, Michael, Murren, John, Dupont, Jakob, Pezzulli, Sandra, Aghajanian, Carol, Sabbatini, Paul, Mendelson, David, Schwartz, Lawrence, Gettinger, Scott, Psyrri, Amanda, Cedarbaum, Jesse M., Spriggs, David R.
Publicado em 2009

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion

Por Rao, Thapi D., Tian, Huasong, Ma, Xun, Yan, Xiujun, Thapi, Sahityasri, Schultz, Nikolaus, Rosales, Nestor, Monette, Sebastien, Wang, Amy, Hyman, David M., Levine, Douglas A., Solit, David, Spriggs, David R.
Publicado no PLoS One (2015)

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Por Zang, Xingxing, Sullivan, Peggy S, Soslow, Robert A, Waitz, Rebecca, Reuter, Victor E, Wilton, Andrew, Thaler, Howard T, Arul, Manonmani, Slovin, Susan F, Wei, Joyce, Spriggs, David R, Dupont, Jakob, Allison, James P
Publicado em 2010

Outcomes of Primary Surgical Cytoreduction in Patients with BRCA-associated High-grade Serous Ovarian Carcinoma

Por Hyman, David M., Long, Kara C., Tanner, Edward J., Grisham, Rachel N., Arnold, Angela G., Bhatia, Jasmine, Phillips, Mary F., Spriggs, David R., Soslow, Robert A., Kauff, Noah D., Levine, Douglas A.
Publicado em 2012

BRAF Mutation is Associated with Early Stage Disease and Improved Outcome in Patients with Low-Grade Serous Ovarian Cancer

Por Grisham, Rachel N., Iyer, Gopa, Garg, Karuna, Delair, Deborah, Hyman, David M., Zhou, Qin, Iasonos, Alexia, Berger, Michael F., Dao, Fanny, Spriggs, David R., Levine, Douglas A., Aghajanian, Carol, Solit, David B.
Publicado em 2012

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Por O’Cearbhaill, Roisin E., Ragupathi, Govind, Zhu, Jianglong, Wan, Qian, Mironov, Svetlana, Yang, Guangbin, Spassova, Maria K., Iasonos, Alexia, Kravetz, Sara, Ouerfelli, Ouathek, Spriggs, David R., Danishefsky, Samuel J., Sabbatini, Paul J.
Publicado no Cancers (Basel) (2016)